vs

Side-by-side financial comparison of IMMUCELL CORP (ICCC) and NVE CORP (NVEC). Click either name above to swap in a different company.

NVE CORP is the larger business by last-quarter revenue ($6.2M vs $5.5M, roughly 1.1× IMMUCELL CORP). NVE CORP runs the higher net margin — 54.4% vs -2.5%, a 56.9% gap on every dollar of revenue. On growth, NVE CORP posted the faster year-over-year revenue change (22.9% vs -8.4%). IMMUCELL CORP produced more free cash flow last quarter ($-1.8M vs $-4.8M). Over the past eight quarters, IMMUCELL CORP's revenue compounded faster (3.9% CAGR vs -6.3%).

ImmuCell Corp is a US-based animal health biotechnology company that develops, manufactures and markets innovative products for livestock, primarily dairy cattle. Its core offerings include preventive and therapeutic solutions for common bovine health issues such as mastitis, serving agricultural producers and veterinary providers across North America.

NVE Corporation develops and manufactures spintronic-based electronic components, including high-performance magnetoresistive sensors, couplers, and signal isolators. Its products are used in industrial automation, automotive systems, medical devices, and IoT applications, serving global original equipment manufacturers and electronic component distributors.

ICCC vs NVEC — Head-to-Head

Bigger by revenue
NVEC
NVEC
1.1× larger
NVEC
$6.2M
$5.5M
ICCC
Growing faster (revenue YoY)
NVEC
NVEC
+31.4% gap
NVEC
22.9%
-8.4%
ICCC
Higher net margin
NVEC
NVEC
56.9% more per $
NVEC
54.4%
-2.5%
ICCC
More free cash flow
ICCC
ICCC
$3.0M more FCF
ICCC
$-1.8M
$-4.8M
NVEC
Faster 2-yr revenue CAGR
ICCC
ICCC
Annualised
ICCC
3.9%
-6.3%
NVEC

Income Statement — Q3 FY2025 vs Q3 FY2026

Metric
ICCC
ICCC
NVEC
NVEC
Revenue
$5.5M
$6.2M
Net Profit
$-139.7K
$3.4M
Gross Margin
42.9%
78.6%
Operating Margin
0.4%
60.2%
Net Margin
-2.5%
54.4%
Revenue YoY
-8.4%
22.9%
Net Profit YoY
80.1%
11.0%
EPS (diluted)
$-0.02
$0.70

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ICCC
ICCC
NVEC
NVEC
Q4 25
$6.2M
Q3 25
$5.5M
$6.3M
Q2 25
$6.4M
$6.1M
Q1 25
$8.1M
$7.3M
Q4 24
$7.8M
$5.1M
Q3 24
$6.0M
$6.8M
Q2 24
$5.5M
$6.8M
Q1 24
$7.3M
$7.1M
Net Profit
ICCC
ICCC
NVEC
NVEC
Q4 25
$3.4M
Q3 25
$-139.7K
$3.3M
Q2 25
$501.9K
$3.6M
Q1 25
$1.4M
$3.9M
Q4 24
$3.0M
Q3 24
$-701.7K
$4.0M
Q2 24
$-1.5M
$4.1M
Q1 24
$-437.9K
$3.8M
Gross Margin
ICCC
ICCC
NVEC
NVEC
Q4 25
78.6%
Q3 25
42.9%
78.3%
Q2 25
43.7%
80.6%
Q1 25
41.6%
79.2%
Q4 24
36.5%
84.2%
Q3 24
26.3%
86.0%
Q2 24
22.5%
85.6%
Q1 24
31.6%
75.5%
Operating Margin
ICCC
ICCC
NVEC
NVEC
Q4 25
60.2%
Q3 25
0.4%
57.6%
Q2 25
8.8%
62.0%
Q1 25
13.9%
58.4%
Q4 24
8.0%
58.5%
Q3 24
-9.6%
65.0%
Q2 24
-25.3%
64.7%
Q1 24
-4.1%
57.3%
Net Margin
ICCC
ICCC
NVEC
NVEC
Q4 25
54.4%
Q3 25
-2.5%
52.2%
Q2 25
7.8%
58.6%
Q1 25
17.9%
53.5%
Q4 24
60.2%
Q3 24
-11.7%
59.6%
Q2 24
-28.0%
60.4%
Q1 24
-6.0%
53.8%
EPS (diluted)
ICCC
ICCC
NVEC
NVEC
Q4 25
$0.70
Q3 25
$-0.02
$0.68
Q2 25
$0.06
$0.74
Q1 25
$0.16
$0.80
Q4 24
$0.09
$0.63
Q3 24
$-0.09
$0.83
Q2 24
$-0.20
$0.85
Q1 24
$-0.06
$0.78

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ICCC
ICCC
NVEC
NVEC
Cash + ST InvestmentsLiquidity on hand
$3.9M
$20.6M
Total DebtLower is stronger
$9.5M
Stockholders' EquityBook value
$29.8M
$58.3M
Total Assets
$45.7M
$60.0M
Debt / EquityLower = less leverage
0.32×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ICCC
ICCC
NVEC
NVEC
Q4 25
$20.6M
Q3 25
$3.9M
$17.7M
Q2 25
$15.8M
Q1 25
$21.7M
Q4 24
$3.8M
$20.4M
Q3 24
$22.9M
Q2 24
$1.3M
$21.7M
Q1 24
$960.3K
$22.2M
Total Debt
ICCC
ICCC
NVEC
NVEC
Q4 25
Q3 25
$9.5M
Q2 25
Q1 25
$8.7M
Q4 24
$9.0M
Q3 24
$9.4M
Q2 24
$9.8M
Q1 24
$10.2M
Stockholders' Equity
ICCC
ICCC
NVEC
NVEC
Q4 25
$58.3M
Q3 25
$29.8M
$59.7M
Q2 25
$29.9M
$61.1M
Q1 25
$29.0M
$62.3M
Q4 24
$27.5M
$63.0M
Q3 24
$26.4M
$64.9M
Q2 24
$23.5M
$64.9M
Q1 24
$24.6M
$65.6M
Total Assets
ICCC
ICCC
NVEC
NVEC
Q4 25
$60.0M
Q3 25
$45.7M
$61.5M
Q2 25
$46.7M
$63.6M
Q1 25
$45.6M
$64.3M
Q4 24
$45.1M
$64.6M
Q3 24
$44.4M
$65.9M
Q2 24
$41.9M
$66.7M
Q1 24
$43.1M
$66.8M
Debt / Equity
ICCC
ICCC
NVEC
NVEC
Q4 25
Q3 25
0.32×
Q2 25
Q1 25
0.30×
Q4 24
0.33×
Q3 24
0.36×
Q2 24
0.42×
Q1 24
0.41×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ICCC
ICCC
NVEC
NVEC
Operating Cash FlowLast quarter
$-1.2M
$4.2M
Free Cash FlowOCF − Capex
$-1.8M
$-4.8M
FCF MarginFCF / Revenue
-32.3%
-77.0%
Capex IntensityCapex / Revenue
10.8%
144.3%
Cash ConversionOCF / Net Profit
1.24×
TTM Free Cash FlowTrailing 4 quarters
$715.4K
$-5.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ICCC
ICCC
NVEC
NVEC
Q4 25
$4.2M
Q3 25
$-1.2M
$2.8M
Q2 25
$1.6M
$5.2M
Q1 25
$1.6M
$2.5M
Q4 24
$-3.1K
$3.8M
Q3 24
$-639.3K
$2.1M
Q2 24
$581.8K
$5.9M
Q1 24
$418.5K
$3.1M
Free Cash Flow
ICCC
ICCC
NVEC
NVEC
Q4 25
$-4.8M
Q3 25
$-1.8M
$2.7M
Q2 25
$1.4M
$4.1M
Q1 25
$1.2M
$-7.5M
Q4 24
$-199.3K
$-6.3M
Q3 24
$-727.7K
$1.9M
Q2 24
$471.0K
$4.9M
Q1 24
$348.1K
FCF Margin
ICCC
ICCC
NVEC
NVEC
Q4 25
-77.0%
Q3 25
-32.3%
42.9%
Q2 25
22.4%
67.7%
Q1 25
15.4%
-103.7%
Q4 24
-2.6%
-124.7%
Q3 24
-12.1%
28.5%
Q2 24
8.6%
72.8%
Q1 24
4.8%
Capex Intensity
ICCC
ICCC
NVEC
NVEC
Q4 25
144.3%
Q3 25
10.8%
1.1%
Q2 25
2.4%
17.3%
Q1 25
4.1%
137.9%
Q4 24
2.5%
200.6%
Q3 24
1.5%
3.1%
Q2 24
2.0%
13.5%
Q1 24
1.0%
0.0%
Cash Conversion
ICCC
ICCC
NVEC
NVEC
Q4 25
1.24×
Q3 25
0.84×
Q2 25
3.19×
1.45×
Q1 25
1.09×
0.64×
Q4 24
1.26×
Q3 24
0.53×
Q2 24
1.43×
Q1 24
0.82×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons